Puff Puff Post

MARCH 2, 2020

Source: New Frontier Data). · Domestic quotas represent a further milestone in the Company’s stated timeline to bring the first medical cannabis products to market in Colombia, targeting patients with two priority conditions; chronic pain and nausea associated with chemotherapy. SOURCE Khiron Life Sciences Corp.

Extraction 52

Extraction THC Chronic Pain Cultivation 52

Puff Puff Post

MARCH 2, 2020

Source: New Frontier Data). · Domestic quotas represent a further milestone in the Company’s stated timeline to bring the first medical cannabis products to market in Colombia, targeting patients with two priority conditions; chronic pain and nausea associated with chemotherapy. SOURCE Khiron Life Sciences Corp.

Extraction 40

Extraction THC Chronic Pain Cultivation 40

Greenspoon Marder Cannabis Law Group Blog

APRIL 2, 2019

For example, we’re seeking comments, data and information on a variety of topics including: what levels of cannabis and cannabis-derived compounds cause safety concerns; how the mode of delivery (e.g., For Alzheimer’s patients, CBD is one treatment option that is slowing the progression of that disease.”.

CBD 40

CBD Research and Development Safety Therapy 40

CannaMD

AUGUST 19, 2020

While COVID-19 can be deadly, the World Health Organization (WHO) stresses that most patients experience mild cases and/or survive: Most people who get COVID-19 have mild or moderate symptoms and can recover thanks to supportive care. Our initial data suggest that some C. Note: Study extracts were applied via media.

Research and Development 141

Research and Development Marijuana Extraction Terpenes 141

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Available at: www.fda.gov/media/131878/download.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JANUARY 20, 2022

Academic trials of oral psilocybin revealed considerable variability in patients’ absorption and metabolism rates at identical doses, which may result in unpredictable pharmacokinetics and pharmacodynamics. Third-party clinical studies investigating oral psilocybin have reported compelling anti-depressant effects. II is a $287.5

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. At the same time, the outlook on cannabis research data is largely positive. Refractory paediatric epilepsy.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

DECEMBER 20, 2021

First Patient Expected to be Enrolled by Q2 of 2022. Data To Support Regulatory Filings in the United States. The study will take place in Canada with a CTA filing and enrollment of the first patient anticipated by Q2 of 2022. Media: Laura Radocaj. BERWYN, Pa.–(BUSINESS About Altasciences. Forward-Looking Statement.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

Cannabis Law Report

JULY 12, 2019

As reported in the Guardian, Analytical Cannabis emphasises the importance of this for those suffering from conditions such as chronic pain, epilepsy and neurological and psychiatric disorders who have long been seeking access to what they hope is a transformative medicine. Background to the legalisation of medical cannabis in the UK.

Epilepsy 40

Epilepsy Medicine Clinical Trials Chronic Pain 40

Cannabis Law Report

NOVEMBER 10, 2021

“We are encouraged with the progress that has been made under the CRADA with NCATS and the NIH Helping to End Addiction Long-term (HEAL) initiative, as we believe that it may help Virpax develop an effective and safe alternative to conventional opioids used by patients to manage acute and chronic pain. Media: Laura Radocaj. Betsy Brod.

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

Cannabis Law Report

SEPTEMBER 1, 2022

The CUP’s current list of qualifying conditions includes cancer, PTSD, epilepsy and hundreds of neurodegenerative diseases but excludes the many other patients who could benefit from the proven power of medical cannabis to treat chronic pain. of cannabis patients. “The data is clear. An additional 45.9%

Chronic Pain 52

Chronic Pain Programs Patients Conditions 52

Cannabis Law Report

AUGUST 31, 2022

The CUP’s current list of qualifying conditions includes cancer, PTSD, epilepsy and hundreds of neurodegenerative diseases but excludes the many other patients who could benefit from the proven power of medical cannabis to treat chronic pain. of cannabis patients. The data is clear. An additional 45.9%

Chronic Pain 52

Chronic Pain Programs Patients Conditions 52

StrainConnect

FEBRUARY 8, 2019

From cancer(11) to epilepsy(12), there seems to be very little that cannabis cannot help with. Now, remember that everyone is different, and new patients will likely still “get high” from products that combine both THC and CBD. Endocannabinoids and epilepsy - Science Direct. How is CBD really helpful? NCBI - NIH.

Hemp 57

Hemp CBD Cannabinoids Sativa 57

NORML

AUGUST 26, 2019

Virginia has been one of the most reluctant states to consider marijuana law reform, though it recently began allowing some forms of cannabis oil for approved patients. And, 2019’s SB 1557 makes it possible for patients to get as much as 10mg of THC in each dose — the same limit as one serving size for edibles in adult-use states.

Marijuana 202

Marijuana Legalization Programs Oil 202